Back to Search Start Over

FDA clears IND for Compugen's COM503 triggering USD30m milestone

Source :
M2 Pharma. July 29, 2024
Publication Year :
2024

Abstract

M2 PHARMA-July 29, 2024-FDA clears IND for Compugen's COM503 triggering USD30m milestone (C)2024 M2 COMMUNICATIONS Clinical-stage therapeutic discovery and development company Compugen Ltd. (Nasdaq:CGEN) (TASE:CGEN) announced on Monday the FDA [...]

Subjects

Subjects :
Gilead Sciences Inc. -- Product development
Compugen Ltd. -- Product development
Biological products industry -- Product development
Protein binding
Biotechnology industry -- Product development
Chemistry

Details

Language :
English
Database :
Gale General OneFile
Journal :
M2 Pharma
Publication Type :
News
Accession number :
edsgcl.802941888

Tools

Authors Abstract Subjects Details